CDXS Codexis Inc.

17.59
-0.53  -3%
Previous Close 18.11
Open 18
Price To Book 10.05
Market Cap 1,029,040,876
Shares 58,518,105
Volume 459,766
Short Ratio
Av. Daily Volume 342,499
Stock charts supplied by TradingView

NewsSee all news

  1. Codexis Attends Opening Ceremony for Porton's Fermentation Pilot Lab in Chongqing

    CHONGQING, China, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS) today announced that it has attended the official opening of Porton Pharma Solutions Ltd.'s (SZSE: 300363) fermentation pilot laboratory

  2. Codexis and Nestlé Health Science Sign Development Agreement to Advance Therapeutic Candidate towards Clinical Studies and Extend Strategic Collaboration Agreement

    REDWOOD CITY, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company and developer of novel biotherapeutics, and Nestlé Health Science, a globally recognized leader

  3. Codexis Announces License Agreement with Roche for Enzyme Used in Next Generation Sequencing

    REDWOOD CITY, Calif., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces a license agreement to provide Roche with Codexis' EvoT4TM DNA ligase

  4. Codexis Announces the Publication with Merck of an Efficient Enzymatic Cascade Process for Synthesis of Investigational Anti-HIV Agent, Islatravir

    REDWOOD CITY, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces the publication with Merck, known as MSD outside the United States and Canada, of a

  5. Codexis Reports Third Quarter 2019 Financial Results

    Total revenues rose 29% to $21.9 million driven by strength in R&D, product, and CodeEvolver® licensing revenues Eleven customers each contributed at least a quarter million dollars in revenue Conference call

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 trial met endpoints - November 8, 2018.
CDX-6114
Phenylketonuria (PKU)

Latest News

  1. Codexis Attends Opening Ceremony for Porton's Fermentation Pilot Lab in Chongqing

    CHONGQING, China, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS) today announced that it has attended the official opening of Porton Pharma Solutions Ltd.'s (SZSE: 300363) fermentation pilot laboratory

  2. Codexis and Nestlé Health Science Sign Development Agreement to Advance Therapeutic Candidate towards Clinical Studies and Extend Strategic Collaboration Agreement

    REDWOOD CITY, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company and developer of novel biotherapeutics, and Nestlé Health Science, a globally recognized leader

  3. Codexis Announces License Agreement with Roche for Enzyme Used in Next Generation Sequencing

    REDWOOD CITY, Calif., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces a license agreement to provide Roche with Codexis' EvoT4TM DNA ligase

  4. Codexis Announces the Publication with Merck of an Efficient Enzymatic Cascade Process for Synthesis of Investigational Anti-HIV Agent, Islatravir

    REDWOOD CITY, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces the publication with Merck, known as MSD outside the United States and Canada, of a

  5. Codexis Reports Third Quarter 2019 Financial Results

    Total revenues rose 29% to $21.9 million driven by strength in R&D, product, and CodeEvolver® licensing revenues Eleven customers each contributed at least a quarter million dollars in revenue Conference call

  6. Codexis to Participate in Four Investment Conferences in November

    REDWOOD CITY, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that management will participate in four upcoming investment conferences: 10th

  7. Codexis to Hold Third Quarter 2019 Conference Call on November 5

    REDWOOD CITY, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will report third quarter 2019 financial results after market close on

  8. Codexis' Protein Engineering Forum Highlights Progress and Future Direction of the Field

    REDWOOD CITY, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, assembled approximately 150 top scientists in protein engineering to discuss recent progress

  9. Codexis Spreading the Promise of Engineered Proteins at SynBioBeta Summit

    Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, is contributing resources and expertise to communicate protein engineering's vast potential at SynBioBeta's Global Synthetic Biology Summit in San

  10. Codexis to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    REDWOOD CITY, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that management will present at the 2019 Cantor Fitzgerald Global Healthcare